ANDA 220121, held by Biocon Pharma Limited. Cabozantinib.
As of Nov 15, 2026, ANDA 220121 (Cabozantinib), held by Biocon Pharma Limited, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 17, 2026 | Original application | Tentative approval | None posted |
| Cabozantinib20MG · tablet | Cabozantinib | None (tentative approval) |
| Cabozantinib40MG · tablet | Cabozantinib | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters